Seminal, Highly Anticipated Alzheimer ' s Trial Falters Seminal, Highly Anticipated Alzheimer ' s Trial Falters

Top-line results from the phase 2/3 DIAN-TU trial show that neither of two investigational drugs met primary or key secondary outcomes in patients with dominantly inherited Alzheimer ' s disease.Medscape Medical News
Source: Medscape Psychiatry Headlines - Category: Psychiatry Tags: Neurology & Neurosurgery News Source Type: news